Results 101 to 110 of about 662,207 (147)

Low baseline HbA1c and reduced eGFR are associated with relatively unfavorable body recomposition after SGLT2 inhibitor therapy in type 2 diabetes. [PDF]

Front Endocrinol (Lausanne)
Gobaru M, Hasuzawa N, Kurinami N, Wada N, Wang L, Nagayama A, Ashida K, Moriyama Y, Jinnouchi H, Nomura M.   +9 more
europepmc   +1 more source

Association of SGLT2 Inhibitor Use with Glycosuria, Pyuria, Urinary Symptoms, and Significant Urine Culture Positivity in Adults with Type 2 Diabetes: A Prospective Cross-Sectional Study. [PDF]

Medicina (Kaunas)
Tüzün T, Eraydın A.
europepmc   +1 more source

SGLT2 inhibitor therapy and clinical outcomes in HIV-related cardiomyopathy. [PDF]

Am Heart J Plus
Sheashaa H, Ibrahim R, Pham HN, Awad K, Scalia IG, Farina JM, Tamarappoo B, Holloway C, Arsanjani R, Ayoub C.   +9 more
europepmc   +1 more source

Pharmacist Outreach and SGLT2 Inhibitor Uptake in Patients With Diabetes and Chronic Kidney Disease.

JAMA Netw Open
Pestka DL, Murphy D, Kaplan AN, Taylor BC, Huynh P, Rechtzigel JA, Kjos S, Ellich LM, Atwood M, Polsfuss BA, Thomas AR, Lee JY, Ishani A.   +12 more
europepmc   +1 more source

Heterogeneous Kidney Patterns in Diabetic Patients Following SGLT2 Inhibitor Use. [PDF]

J Korean Med Sci
Bae S, Yun D, Kim J, Park S, Kim YC, Kim DK, Oh KH, Joo KW, Kim YS, Han SS.   +9 more
europepmc   +1 more source

From glucosuria to dialysis: a case report of osmotic nephropathy due to an SGLT2 inhibitor. [PDF]

BMC Nephrol
Castellanos-de la Hoz J, Molano-Triviño A, González-García YF, Espinosa Saltaren LM, Zúñiga-Rodríguez E.   +4 more
europepmc   +1 more source

Safety and clinical impact of SGLT2 inhibitor in patients undergoing peritoneal dialysis: a target-trial emulation study. [PDF]

Clin Kidney J
Chen YT, Wang CA, Chen JY, Wu VC.
europepmc   +1 more source

The SGLT2 inhibitor checklist: a comprehensive review of perioperative and acute phase safety management. [PDF]

Front Endocrinol (Lausanne)
Deng B, Liu W, Chu Q.
europepmc   +1 more source

Association of SGLT2 Inhibitor Use with All-Cause Mortality Following CIED Implantation for Conduction Disease in Patients with Preserved LVEF: A Retrospective Cohort Study. [PDF]

J Clin Med
Arabaci HO, Ozkan F, Guven Z, Gecit MH, Arslan S, Arslan S.   +5 more
europepmc   +1 more source

SGLT2 inhibitor therapy is associated with IL-10/TGF-α/sVEGFR3 signalling and adipose tissue remodelling in advanced heart failure. [PDF]

J Mol Cell Cardiol Plus
Cinkajzlova A, Kasperova BJ, Ivak P, Netuka I, Melenovsky V, Mrazova LS, Stranecky V, Mraz M, Stemberkova Hubackova S, Haluzik M.   +9 more
europepmc   +1 more source